When a Professional Might Recommend Spravato for Depression and What You Can Expect

Managing major depressive disorder can be daunting, especially when traditional oral medications do not provide sufficient relief. That is why psychiatrists may introduce Spravato for depression® for those experiencing persistent symptoms. Understanding this alternative therapeutic option can guide patients toward an effective treatment path.

Understanding treatment-resistant conditions

Psychiatrists consider Spravato for depression primarily when a patient experiences treatment-resistant depression (TRD). This classification applies when an individual has tried at least two different oral antidepressant medications of adequate dose and duration during a current moderate-to-severe depressive episode without significant improvement. When standard options fail to change the severity of symptoms, exploring a different chemical mechanism becomes necessary.

Spravato (esketamine) is a nasal spray that targets the N-methyl-D-aspartate receptors in the brain. Unlike traditional antidepressants that focus on altering neurotransmitters such as serotonin or norepinephrine, this approach modulates glutamate pathways to help restore synaptic connections (where nerves communicate with one another). A psychiatrist can evaluate a patient's treatment history to determine if their condition meets the clinical criteria for this specialized intervention.

The preparation and assessment process

Before initiating therapy, individuals undergo a comprehensive clinical evaluation to ensure the protocol aligns with their medical history. Psychiatrists review current medications, structural health conditions, and potential risks, such as a history of vascular issues or substance misuse. This assessment ensures that the nasal spray can be administered properly within a structured environment.

Spravato (esketamine) treatment can be used in two ways, depending on a patient’s diagnosis. For treatment-resistant depression, Spravato is now FDA-approved as a standalone monotherapy, meaning that patients no longer have to take a daily oral antidepressant to benefit from treatment. That said, it can also still be used in combination with an oral antidepressant when that approach better fits a patient’s history and treatment goals.

Additionally, for patients with a history of major depressive disorder with suicidal ideation or behavior, Spravato is used alongside an oral antidepressant. Combining these approaches helps sustain the neurological benefits and progress achieved during active treatment sessions.

After approval, our clinical team builds a personalized treatment schedule. Most patients begin with an induction phase requiring two in-office visits per week for the first month, followed by a maintenance phase with less frequent sessions.

What to expect during a Spravato administration session

Every treatment session takes place entirely within a certified healthcare facility under direct clinical supervision. Patients administer the nasal spray themselves under the guidance of a psychiatrist or clinical team member who monitors the proper technique. Since the medication can cause transient changes in blood pressure and temporary dissociative effects, patients remain in the office for observation. From start to finish, patients can expect the following:

• Pre-treatment check: The medical team measures blood pressure before administering the nasal spray.
• Medication administration: The patient utilizes the device to deliver the prescribed dose into each nostril.
• Observation period: The patient rests in a comfortable chair for at least two hours while team members monitor their physical responses.
• Post-treatment evaluation: A final check ensures blood pressure readings are stable before the patient is cleared to leave.

Due to the sedating effects of the medication, patients cannot drive themselves home and must arrange for a designated driver following every visit.

Expected timeline and long-term maintenance

The therapeutic timeline varies based on individual responses, but many patients notice improvements within the first few weeks. After the initial four-week induction phase, the session frequency generally decreases to once a week or once every two weeks during the maintenance phase. Ongoing evaluations help the psychiatrist determine the total duration of the treatment plan.

Book a consultation today

Exploring advanced therapeutic options can offer new possibilities for managing chronic mental health struggles. By discussing Spravato for depression with our psychiatrist, you can discover a structured framework designed to address stubborn symptoms and improve daily functioning. For more information or to schedule an appointment, call our office.

To schedule a consultation, please request an appointment on our website at https://futurepsychsolutions.com or call Future Psych Solutions at (803) 335-5232 to arrange an appointment at our Columbia office.

Click here to see if you’re a candidate

Check out what others are saying about our services on Yelp: Read our Yelp reviews.